Table 2

Productivity losses during the year (=365 days) before the day of treatment initiation

Cohort I (mono DMARD)Cohort II (combo DMARD)Cohort III (biological agents (RA <5 years))Cohort IV (biological agents (all))
N279697316004787
Any disability pension (%)10122143
Any sick leave ≥14 days (%)59676753
Any disability pension or sick leave (%)64727880
Mean days (95% CI)
Total days78 (74 to 82)132 (124 to 140)171 (164 to 178)190 (186 to 194)
 Days on disability pension25 (21 to 28)27 (22 to 32)51 (46 to 57)111 (107 to 115)
 Days on sick leave54 (50 to 57)105 (98 to 113)120 (113 to 126)79 (76 to 82)
Median days (25th–75th percentile)
Total days26 (0–111)93 (0–231)156 (13–336)183 (30–365)
 Days on disability pension0 (0–0)0 (0–0)0 (0–0)0 (0–183)
 Days on sick leave15 (0–75)58 (0–186)70 (0–220)11 (0–129)
  • Patients initiating treatment 1999–2007 and registered in the Swedish Rheumatology Quality Register, including the Swedish Biologics Register ARTIS.

    DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.